Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β In Vivo by Immunotherapy
暂无分享,去创建一个
B. Hyman | B. Bacskai | P. Seubert | D. Schenk | D. Games | M. E. McLellan | S. Kajdasz | M. McLellan
[1] David J. Cummins,et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[2] L. Mucke,et al. TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice , 2001, Nature Medicine.
[3] Brian J. Bacskai,et al. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy , 2001, Nature Medicine.
[4] B T Hyman,et al. Growth Arrest of Individual Senile Plaques in a Model of Alzheimer's Disease Observed by In Vivo Multiphoton Microscopy , 2001, The Journal of Neuroscience.
[5] Ralph A. Nixon,et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.
[6] J. Hardy,et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.
[7] R. Motter,et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.
[8] B. Solomon,et al. Modulation of Alzheimer’s β-amyloid neurotoxicity by site-directed single-chain antibody , 2000, Journal of Neuroimmunology.
[9] L. Mucke,et al. Elimination of the class A scavenger receptor does not affect amyloid plaque formation or neurodegeneration in transgenic mice expressing human amyloid protein precursors. , 1999, The American journal of pathology.
[10] R. Motter,et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.
[11] R G Shulman,et al. Dynamic mapping at the laminar level of odor-elicited responses in rat olfactory bulb by functional MRI. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[12] J. Trojanowski,et al. Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.
[13] D. Rubinsztein. The genetics of Alzheimer's disease , 1997, Progress in Neurobiology.
[14] W. Markesbery. Neuropathological Criteria for the Diagnosis of Alzheimer’s Disease , 1997, Neurobiology of Aging.
[15] J. Powers,et al. Diagnostic Criteria for the Neuropathologic Assessment of Alzheimer’s Disease , 1997, Neurobiology of Aging.
[16] B. Solomon,et al. Disaggregation of Alzheimer β-amyloid by site-directed mAb , 1997 .
[17] M. Tabaton,et al. Is amyloid β‐protein glycated in Alzheimer's disease? , 1997 .
[18] J. Thome,et al. Advanced glycation endproducts in ageing and Alzheimer's disease , 1997, Brain Research Reviews.
[19] S. Younkin,et al. Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.
[20] B. Solomon,et al. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[21] L. Mucke,et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.
[22] W. Denk,et al. Two-photon laser scanning fluorescence microscopy. , 1990, Science.
[23] B. Sommer,et al. Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. , 2001, The American journal of pathology.
[24] D. Holtzman,et al. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[25] J. Hardy,et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. , 2000, Nature.
[26] P. S. St George-Hyslop,et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. , 2000, Nature.
[27] B. Solomon,et al. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[28] M. Tabaton,et al. Is amyloid beta-protein glycated in Alzheimer's disease? , 1997, Neuroreport.
[29] D. Selkoe. Cell biology of the beta-amyloid precursor protein and the genetics of Alzheimer's disease. , 1996, Cold Spring Harbor symposia on quantitative biology.